MARKET

MRNS

MRNS

Marinus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.85
+0.36
+1.95%
Opening 11:06 06/24 EDT
OPEN
18.61
PREV CLOSE
18.49
HIGH
18.96
LOW
18.61
VOLUME
51.23K
TURNOVER
--
52 WEEK HIGH
20.04
52 WEEK LOW
6.04
MARKET CAP
690.54M
P/E (TTM)
-7.4710
1D
5D
1M
3M
1Y
5Y
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to five new employees. The Compensation Committee of t...
Business Wire · 1d ago
Here's Why We're Not Too Worried About Marinus Pharmaceuticals' (NASDAQ:MRNS) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Simply Wall St. · 06/15 08:55
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual invest...
Business Wire · 06/11 11:30
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. M...
GlobeNewswire · 05/19 11:00
Marinus Pharmaceuticals: Q1 Earnings Insights
  Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share decreased 131.25% over the past year to ($0.74), which missed the estimate of ($0.45).
Benzinga · 05/17 11:46
Marinus Pharmaceuticals EPS misses by $0.29, misses on revenue; issues FY 2021 guidance
Marinus Pharmaceuticals (MRNS): Q1 GAAP EPS of -$0.74 misses by $0.29.Revenue of $1.81M misses by $0.75M.Cash, cash equivalents, and investments of $123.5M.The company believes its cash and cash equivalents as
Seekingalpha · 05/17 11:38
BRIEF-Marinus Pharmaceuticals Reports Qtrly Loss Per Share Of $0.74
reuters.com · 05/17 11:36
Marinus Pharmaceuticals Q1 EPS $(0.74) Misses $(0.45) Estimate, Sales $1.81M Miss $2.57M Estimate
Marinus Pharmaceuticals (NASDAQ:MRNS) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.45) by 64.44 percent. This is a 131.25 percent decrease over losses of $(0.32) per
Benzinga · 05/17 11:36
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNS. Analyze the recent business situations of Marinus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNS stock price target is 29.56 with a high estimate of 38.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 146
Institutional Holdings: 43.14M
% Owned: 117.77%
Shares Outstanding: 36.63M
TypeInstitutionsShares
Increased
43
2.65M
New
12
507.68K
Decreased
18
835.54K
Sold Out
12
2.27M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.11%
Pharmaceuticals & Medical Research
+1.29%
Key Executives
Non-Executive Chairman/Independent Director
Nicole Vitullo
President/Chief Executive Officer/Director
Scott Braunstein
Chief Financial Officer/Treasurer
Steven Pfanstiel
Vice President/General Counsel/Secretary
Martha Manning
Other
Joseph Hulihan
Vice President/Director of Investor Relations
Sasha Damouni Ellis
Independent Director
Charles Austin
Independent Director
Enrique Carrazana
Other
Christy Shafer
Independent Director
Michael Dougherty
Independent Director
Elan Ezickson
Independent Director
Seth Fischer
Independent Director
Timothy Mayleben
Independent Director
Saraswathy Nochur
No Data
About MRNS
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNS stock methods without spending real money on the virtual paper trading platform.